Market Cap 93.46M
Revenue (ttm) 0.00
Net Income (ttm) -20.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.07
Volume 1,263,000
Avg Vol 869,166
Day's Range N/A - N/A
Shares Out 38.46M
Stochastic %K 1%
Beta -0.03
Analysts Strong Sell
Price Target $7.60

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 500 1556
Address:
4800 Montgomery Lane, Suite 220, Bethesda, United States
Dave2468999077844
Dave2468999077844 Mar. 16 at 12:57 PM
$GANX lookin for a big move higher. could double easily in a split second.
0 · Reply
plv2000
plv2000 Mar. 16 at 12:40 PM
$GANX the upfront cash in any licensing deal is the key. $100M=$7 or $200M=$15.
1 · Reply
MQuick
MQuick Mar. 16 at 12:22 PM
$GANX lets see what games they have in store today
0 · Reply
afifee
afifee Mar. 16 at 12:10 PM
$GANX popped up on my watchlist earlier.
0 · Reply
Pacsbull
Pacsbull Mar. 16 at 12:08 PM
0 · Reply
Jwelz90
Jwelz90 Mar. 16 at 12:06 PM
$GANX Talking about small bio and Parkinson research on Squawk Box as well about streamlined approval process possibilities.
0 · Reply
ThatDude069
ThatDude069 Mar. 16 at 11:44 AM
$GANX $3 calls expire Friday. At this point we all know what that means
1 · Reply
EdwardBrush1061
EdwardBrush1061 Mar. 16 at 5:06 AM
$GANX is another one I'm casually monitoring today.
0 · Reply
cjcollier26
cjcollier26 Mar. 16 at 12:55 AM
$GANX Gain is setting the stage for an acquisition or major partnership. Big pharmaceutical companies will be weighing in and will see the unprecedented potential that lies within this company. I don’t think this stock will remain at these levels for much longer. Hopefully the upward trend begins this week.
1 · Reply
rustinpeace
rustinpeace Mar. 15 at 10:24 PM
$GANX https://adpd.kenes.com/
0 · Reply
Latest News on GANX
Gain Therapeutics to Present at Neuroscience 2025

Oct 30, 2025, 7:00 AM EDT - 4 months ago

Gain Therapeutics to Present at Neuroscience 2025


Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 16, 2025, 7:00 AM EDT - 5 months ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit


Gain Therapeutics Announces Proposed Public Offering

Jul 15, 2025, 4:36 PM EDT - 8 months ago

Gain Therapeutics Announces Proposed Public Offering


Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 29, 2025, 8:45 AM EDT - 10 months ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting


Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025


Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Mar 6, 2025, 7:55 AM EST - 1 year ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025


Gain Therapeutics To Present At Biotech Showcase 2025

Dec 11, 2024, 8:30 AM EST - 1 year ago

Gain Therapeutics To Present At Biotech Showcase 2025


Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jul 1, 2024, 10:13 AM EDT - 1 year ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript


Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 4:08 PM EDT - 1 year ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO


Dave2468999077844
Dave2468999077844 Mar. 16 at 12:57 PM
$GANX lookin for a big move higher. could double easily in a split second.
0 · Reply
plv2000
plv2000 Mar. 16 at 12:40 PM
$GANX the upfront cash in any licensing deal is the key. $100M=$7 or $200M=$15.
1 · Reply
MQuick
MQuick Mar. 16 at 12:22 PM
$GANX lets see what games they have in store today
0 · Reply
afifee
afifee Mar. 16 at 12:10 PM
$GANX popped up on my watchlist earlier.
0 · Reply
Pacsbull
Pacsbull Mar. 16 at 12:08 PM
0 · Reply
Jwelz90
Jwelz90 Mar. 16 at 12:06 PM
$GANX Talking about small bio and Parkinson research on Squawk Box as well about streamlined approval process possibilities.
0 · Reply
ThatDude069
ThatDude069 Mar. 16 at 11:44 AM
$GANX $3 calls expire Friday. At this point we all know what that means
1 · Reply
EdwardBrush1061
EdwardBrush1061 Mar. 16 at 5:06 AM
$GANX is another one I'm casually monitoring today.
0 · Reply
cjcollier26
cjcollier26 Mar. 16 at 12:55 AM
$GANX Gain is setting the stage for an acquisition or major partnership. Big pharmaceutical companies will be weighing in and will see the unprecedented potential that lies within this company. I don’t think this stock will remain at these levels for much longer. Hopefully the upward trend begins this week.
1 · Reply
rustinpeace
rustinpeace Mar. 15 at 10:24 PM
$GANX https://adpd.kenes.com/
0 · Reply
rustinpeace
rustinpeace Mar. 15 at 10:23 PM
$GANX another red premarket. oil is up to 105. saddle up its gonna be a long week. set it and forget it for now. i might consider buying some more dips though. there is the conference to look forward too. i dont predict a buy out yet though. the more they prove GT-0227 works the more Gain is worth .https://adpd.kenes.com/
0 · Reply
RealMcCoin
RealMcCoin Mar. 15 at 9:51 PM
$GANX is such a funky stock but I sleep well knowing that one morning there will a pr announcing the big pay day!
0 · Reply
Jwa68
Jwa68 Mar. 15 at 9:08 PM
$GANX Achievement of statistical significance should significantly de-risk the possibility of failure, and along with other data in the trial notably, improvement of motor skills and other clinical scores would further support the importance of the data. Another aspect of the trial was that although they collected data on a non-validated end point, investigators & patients were blind with respect to the results to be generated and in this sense, it almost functioned like a blind trial. Lastly. rhe other criticism of the trial that it was open label, but the fact that neither patient or physicians knew what these GLUSPH readings were was a blinded result, and all went in the correct direction so far as I understand. This clewrly would lends credibility to a notional or theoretical approach toward a blinded study in the sense that patients didn’t know what to look for or what was expected, but the data supports the hypothesis that GT-00287 is having an impact on an important enzyme
1 · Reply
Jwa68
Jwa68 Mar. 15 at 9:03 PM
$GANX People can come and they may go, but for investors focussed on the data and who are capable of managing emotions, here are some thoughts to consider. Most don't understand that the company's choice to move forward in a phase 1b clinical trial was to get some signal of efficacy. It most probably was not expected to achieve statistical significance, but rather to show non-statistical trends toward advocacy. The legitimate criticism of this study and approach would be two fold, one that it was not placebo controlled, and that the data would be a small set of information. Fine, but what is surprising is the achievement of statistical significance with a relatively small patient population indicating that if you replicated this study 100 times you would get the same result 95% of the time showing efficacy. This would have to be most encouraging to anyone who’s looking at this and certainly to those who are evaluating a potential transaction to license or co- develop the drug.
2 · Reply
douglas3684
douglas3684 Mar. 15 at 8:19 PM
$GANX Are we getting 10k tomorrow or is it March 31st?
1 · Reply
7e7en
7e7en Mar. 15 at 8:07 PM
$GANX my crystal ball from Amazon says slight strength into presentation then sharp selloff giving back any gains and that’s IF data knocks our socks off, if it’s perceived as anything short of groundbreaking I suspect we will be punished heavily and rightfully so. If they’re getting lowball offers now from parties under NDA who can peek at more fulsome data, why would those same suitors up the bid on further negative market action and response to data? Hard to believe one guy is crushing the share price but another guy or tute can’t counter or at least limit his influence. If we get financing after all of this idk what to say and I know many believe no financing but they also believed new name on door by end of last year, and while that may be supported by data the real world fact is they need cash to do what they’re claiming they’ll do these next few quarters. Not abnormal chain of events for a penny bio but doesn’t make it any more palatable given the narrative on this ticker. 🔮
3 · Reply
Bulldog1776
Bulldog1776 Mar. 15 at 7:19 PM
$GANX this stock should get pumped to $4 next week. Let’s make it happen! It is LEGIT
0 · Reply
MQuick
MQuick Mar. 15 at 7:17 PM
$GANX this past Friday or tomorrow will be the last day of blatant thievery.
0 · Reply
microcapspeculator
microcapspeculator Mar. 15 at 6:51 PM
$GANX One of these days all the attention will be on Gain. At that point the share price will reflect the first Parkinson’s disease modifying drug.
1 · Reply
Jwa68
Jwa68 Mar. 15 at 5:13 PM
$GANX Follow the data, the patients, the scientists, the clinicians, the analysts and the KOL's. There are dozens across all of them, its a growing concensus...just ask one. Things are about to get interesting and Friday was deliberate. If you cannot emotionally handle a 25 cent drop on a stock that you believe could be $20 in the blink of an eye, then just sell and move on. Nobody will fault you and you have every right to. To the contrary, making emotionally laden posts that only illuminates your own ignorance will unfortunately definately get you blocked by many of us. Cavalry is coming and we have a drug. Do what is best for you. Life is short...don't be a dick. 😁
1 · Reply
microcapspeculator
microcapspeculator Mar. 15 at 4:56 PM
$GANX Here is one of the original Gain charts. I think the chart up to Lewy Body and $10B a year could be realistic. This is only the 2m current US patients. But keep in mind being used as a preventative would increase the market size by 10x.
0 · Reply
microcapspeculator
microcapspeculator Mar. 15 at 3:57 PM
$GANX I have yet to see an argument against the data. All posters complain about it the other posters. Not hard to figure who is tied to the 3 million shorted shares. High levels of glucosylsphingosine (GluSph), also known as lyso-Gb1, are a marker of lysosomal dysfunction, specifically associated with Gaucher disease and increasingly recognized as a factor in Dementia with Lewy Bodies (DLB) Here is the connection between Glucosylsphingosine (GluSph) and Lewy Body Dementia: GBA1 Mutations and Lysosomal Dysfunction: The GBA1 gene encodes the lysosomal enzyme -glucocerebrosidase (GCase). Mutations in this gene reduce GCase activity, leading to the accumulation of its substrates, including glucosylceramide and its deacylated form, glucosylsphingosine (GluSph). Significance in LBD/DLB: The accumulation of GluSph, caused by low GCase activity, is believed to contribute to the pathogenic buildup of -synuclein protein, which forms the Lewy bodies characteristic of the disease.
0 · Reply